Membrane-interactive lipids as experimental anticancer drugs.
作者信息
Berdel W E
出版信息
Br J Cancer. 1991 Aug;64(2):208-11. doi: 10.1038/bjc.1991.277.
Abstract
摘要
相似文献
1
Membrane-interactive lipids as experimental anticancer drugs.作为实验性抗癌药物的膜相互作用脂质
Br J Cancer. 1991 Aug;64(2):208-11. doi: 10.1038/bjc.1991.277.
2
Phospholipid antitumor agents.磷脂类抗肿瘤药物。
Med Res Rev. 1995 May;15(3):157-223. doi: 10.1002/med.2610150302.
3
Ether lipids and derivatives as investigational anticancer drugs. A brief review.醚脂类及其衍生物作为抗癌研究药物。简要综述。
Onkologie. 1990 Aug;13(4):245-50. doi: 10.1159/000216771.
4
Ether lipids in the therapy of cancer.醚脂类在癌症治疗中的应用
Prog Biochem Pharmacol. 1988;22:118-31.
5
Advances in either phospholipids treatment of cancer.磷脂在癌症治疗方面的进展。 （注：原英文表述有误，推测正确表述可能是“Advances in the treatment of cancer with phospholipids” ）
Crit Rev Oncol Hematol. 1995 Mar;18(3):155-78. doi: 10.1016/1040-8428(94)00118-d.
6
NMR spectral analysis of cytotoxic ether lipids.细胞毒性醚脂的核磁共振光谱分析
J Lipid Res. 1992 Apr;33(4):605-9.
7
Alkyl ether lipids, ion channels and lipid raft reorganization in cancer therapy.烷基醚脂质、离子通道和脂筏重排在癌症治疗中的作用。
Pharmacol Ther. 2016 Sep;165:114-31. doi: 10.1016/j.pharmthera.2016.06.003. Epub 2016 Jun 8.
8
Edelfosine, apoptosis, MDR and Na+/H+ exchanger: induction mechanisms and treatment implications.艾地福新、细胞凋亡、多药耐药与钠氢交换体：诱导机制及治疗意义
Apoptosis. 2000 Feb;5(1):87-9. doi: 10.1023/a:1009645927931.
9
Purging leukemia remission marrows with alkyl-lysophospholipids, preclinical and clinical results.用烷基溶血磷脂清除白血病缓解期骨髓的临床前和临床结果。
Prog Clin Biol Res. 1990;333:1-18; discussion 19-20.
10
Rationale and clinical application of alkylphospholipid analogues in combination with radiotherapy.烷基磷脂类似物与放疗联合应用的原理及临床应用
Cancer Treat Rev. 2007 Apr;33(2):191-202. doi: 10.1016/j.ctrv.2006.12.001. Epub 2007 Feb 6.
引用本文的文献
1
Impact of targeting the platelet-activating factor and its receptor in cancer treatment.靶向血小板活化因子及其受体在癌症治疗中的作用
Mil Med Res. 2025 Mar 4;12(1):10. doi: 10.1186/s40779-025-00597-0.
2
Activation of Investigator-Initiated Clinical Trials with a Pharmaceutical for Cancer Patients before and after Post-Millennial Changes of Regulations in Germany and Europe.在德国和欧洲千禧年后法规变更前后，一种用于癌症患者的药物的研究者发起的临床试验的启动情况。
Cancers (Basel). 2022 Mar 3;14(5):1308. doi: 10.3390/cancers14051308.
3
Upregulation of cell cycle genes in head and neck cancer patients may be antagonized by erufosine's down regulation of cell cycle processes in OSCC cells.头颈部癌症患者细胞周期基因的上调可能会被依鲁福辛对口腔鳞状细胞癌细胞周期进程的下调所拮抗。
Oncotarget. 2017 Dec 20;9(5):5797-5810. doi: 10.18632/oncotarget.23537. eCollection 2018 Jan 19.
4
Evaluation of in vitro and in vivo anti-inflammatory activity of biologically active phospholipids with anti-neoplastic potential in porcine model.评价具有抗肿瘤潜力的生物活性磷脂在猪模型中的体外和体内抗炎活性。
BMC Complement Altern Med. 2014 Sep 19;14:339. doi: 10.1186/1472-6882-14-339.
5
Leishmania donovani resistance to miltefosine involves a defective inward translocation of the drug.杜氏利什曼原虫对米替福新的耐药性涉及该药物向内转运缺陷。
Antimicrob Agents Chemother. 2003 Aug;47(8):2397-403. doi: 10.1128/AAC.47.8.2397-2403.2003.
6
MDR1 causes resistance to the antitumour drug miltefosine.多药耐药蛋白1（MDR1）导致对抗肿瘤药物米托蒽醌产生耐药性。
Br J Cancer. 2001 May 18;84(10):1405-11. doi: 10.1054/bjoc.2001.1776.
7
The ether lipid ET-18-OCH3 increases cytosolic Ca2+ concentrations in Madin Darby canine kidney cells.醚脂ET-18-OCH3可提高马-达二氏犬肾细胞的胞质钙离子浓度。
Br J Pharmacol. 1999 Jul;127(6):1502-10. doi: 10.1038/sj.bjp.0702691.
8
New drugs for BNCT: an experimental approach.用于硼中子俘获疗法的新药：一种实验方法。
Strahlenther Onkol. 1999 Jun;175 Suppl 2:118-20. doi: 10.1007/BF03038909.
9
Cellular uptake and retention measurements of alkylphosphocholines in the SK-BR-3 breast cancer and Molt-4 leukemia cell line using capillary gas chromatography.
Lipids. 1999 May;34(5):511-6. doi: 10.1007/s11745-999-0392-6.
10
Resistance to the new anti-cancer phospholipid ilmofosine (BM 41 440).对新型抗癌磷脂 ilmofosine（BM 41 440）的耐药性。
Br J Cancer. 1997;76(7):862-9. doi: 10.1038/bjc.1997.476.
本文引用的文献
1
The influence of alkyl-lysophospholipids and lysophospholipid-activated macrophages on the development of metastasis of 3-Lewis lung carcinoma.
Eur J Cancer (1965). 1980 Sep;16(9):1199-204. doi: 10.1016/0014-2964(80)90179-6.
2
Induction of differentiation of cultured human and mouse myeloid leukemia cells by alkyl-lysophospholipids.烷基溶血磷脂对培养的人及小鼠髓性白血病细胞的分化诱导作用。
Cancer Res. 1981 Aug;41(8):3211-6.
3
Destruction of human solid tumors by alkyl lysophospholipids.
J Natl Cancer Inst. 1980 Jun;64(6):1301-6. doi: 10.1093/jnci/64.6.1301.
4
Phospholipid-sensitive Ca2+-dependent protein phosphorylation system in various types of leukemic cells from human patients and in human leukemic cell lines HL60 and K562, and its inhibition by alkyl-lysophospholipid.人类患者各类白血病细胞以及人白血病细胞系HL60和K562中的磷脂敏感型钙依赖性蛋白磷酸化系统，及其被烷基溶血磷脂抑制的情况。
Cancer Res. 1983 Jun;43(6):2955-61.
5
Tumor cytotoxicity of human macrophages after incubation with synthetic analogues of 2-lysophosphatidylcholine.
J Natl Cancer Inst. 1984 Jan;72(1):53-9. doi: 10.1093/jnci/72.1.53.
6
Cytotoxicity of thioether-lysophospholipids in leukemias and tumors of human origin.
Cancer Res. 1983 Nov;43(11):5538-43.
7
Alkyl-lysophospholipid induced suppression of human lymphocyte response to mitogens and selective killing of lymphoblasts.烷基溶血磷脂诱导人淋巴细胞对丝裂原的反应受到抑制，并选择性杀伤成淋巴细胞。
Immunobiology. 1980 Jan;156(4-5):498-508. doi: 10.1016/S0171-2985(80)80083-0.
8
Purging murine leukemic marrow with alkyl-lysophospholipids.用烷基溶血磷脂清除小鼠白血病骨髓。
Blood. 1984 Dec;64(6):1288-91.
9
10
Clonogenicity of normal and malignant hematopoietic progenitor cells after exposure to synthetic alkyl-lymphospholipids.正常和恶性造血祖细胞暴露于合成烷基磷脂后的克隆形成能力
Blut. 1985 Dec;51(6):393-9. doi: 10.1007/BF00320725.
Zotero 插件